6.4 KiB
| type | title | author | url | date | domain | secondary_domains | format | status | priority | tags | intake_tier | extraction_model | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| source | Compass Pathways COMP006: Second Positive Phase 3 for Psilocybin in TRD — Two-Dose Protocol, 39% Response, NDA Q4 2026 | Compass Pathways (ir.compasspathways.com) | https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Successfully-Achieves-Primary-Endpoint-in-Second-Phase-3-Trial-Evaluating-COMP360-Psilocybin-for-Treatment-Resistant-Depression/default.aspx | 2026-02-17 | health | press-release | null-result | high |
|
research-task | anthropic/claude-sonnet-4.5 |
Content
Trial: COMP006 — Second Phase 3 Trial of COMP360 Psilocybin for Treatment-Resistant Depression
Design:
- n=568 participants with TRD (≥2 failed antidepressant courses)
- Randomized, double-blind
- North America and European sites
- Two fixed doses administered 3 weeks apart: COMP360 25mg vs. 10mg vs. 1mg (1mg = near-placebo)
- Psychological support protocol embedded
Primary endpoint (MADRS change from baseline at Week 6):
- Two-dose COMP360 25mg vs. 1mg: -3.8 points (p<0.001)
- Highly statistically significant
Response and remission:
- 39% of COMP360 25mg arm achieved ≥25% MADRS reduction (vs. ~23% control group)
- 40%+ of non-remitters after dose 1 achieved remission after dose 2 — clinically important: second dose substantially increases responder pool
- Significant from next day after first dose, maintained at all measured timepoints through week 6
Durability:
- 26-week Part B data expected Q3 2026 (this is the final dataset required for NDA)
Safety:
- Well-tolerated profile confirmed across both COMP005 and COMP006
- All adverse events mild or moderate, most resolving within 24 hours
- Headache, nausea, anxiety, visual hallucination (expected with psilocybin)
NDA timeline:
- 26-week data from Part B: Q3 2026
- Rolling NDA submission completion: Q4 2026
- Commissioner National Priority Voucher (received April 24, 2026): accelerates FDA review
- Expected FDA decision: 2027
- DEA rescheduling: required within 90 days of FDA approval
Additional context:
- FDA also accepted IND application for COMP360 in PTSD (expanding indication pipeline)
- 10mg dose arm showed intermediate results (not separately reported here)
- Psychedelic Alpha noted "modest magnitude raises questions" about clinical significance — MADRS -3.8 vs. -3.6 for COMP005 is consistent but below typical antidepressant effect sizes in Phase 3; however, TRD is an inherently harder-to-treat population and single/dual dose durability is the differentiated value
Agent Notes
Why this matters: Two consecutive positive Phase 3 trials = regulatory package sufficient for NDA. The FDA requires two Phase 3 trials demonstrating efficacy — Compass has now met this bar for the first time for any psychedelic drug. If the 26-week data holds, NDA submission in Q4 2026 would lead to likely FDA approval in 2027, making psilocybin the first FDA-approved psychedelic drug in US history.
What surprised me: The second-dose responder finding — 40%+ of non-remitters after dose 1 achieved remission after dose 2. This suggests that "psilocybin non-responders" after a single dose are not permanent non-responders. This has clinical implications: treat-and-reassess protocol rather than single-dose adequacy judgment.
What I expected but didn't find: Head-to-head data vs. esketamine (Spravato), which is the current FDA-approved TRD option. Spravato (ketamine) requires twice-weekly intranasal dosing with monitored sessions, while COMP360 requires 1-2 full-day sessions. The comparison is commercially and clinically important but not yet published.
KB connections:
- the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access — psilocybin for TRD specifically; workforce implications (psilocybin sessions require trained therapist accompaniment)
- prescription digital therapeutics failed as a business model because FDA clearance creates regulatory cost without the pricing power that justifies it for near-zero marginal cost software — psilocybin is opposite: FDA clearance + high pricing power + durable effect from 1-2 doses
- healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software — by contrast, psilocybin fits the EXISTING FDA drug model well (fixed dose, defined indication, clear endpoint)
Extraction hints:
- Primary claim to extract: "COMP360 psilocybin achieved two consecutive positive Phase 3 trials for treatment-resistant depression, establishing the first FDA-approvable psychedelic with 1-2 dose durability through 26 weeks"
- Quantify: -3.8 MADRS, 39% response rate, 40%+ of non-remitters respond to second dose
- Note the "modest magnitude" debate: statistically significant but MADRS -3.8 is at the lower end of what's considered clinically meaningful in non-TRD populations; appropriate for TRD given difficulty of the population
- Second claim candidate: "psilocybin therapy requires structured psychological support as an integral clinical component, placing it at the clinical/non-clinical interface rather than as pure pharmacotherapy"
Context: Second primary press release from Compass Pathways IR. Confirm with Psychiatric Times and STAT News coverage. Note: 26-week Part B data not yet published — the NDA is contingent on this data holding in Q3 2026.
Curator Notes (structured handoff for extractor)
PRIMARY CONNECTION: the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access WHY ARCHIVED: Completes the Phase 3 regulatory package for psilocybin. The two positive trials together (COMP005 + COMP006) constitute the first FDA-approvable psychedelic drug. Historical significance for psychiatry. EXTRACTION HINT: Extract as a pair with COMP005. The key clinical insight is the two-dose responder finding: patients who don't respond to one dose may respond to a second 3 weeks later. Also flag the "modest effect size" debate — appropriate to note in confidence calibration for any claim.